$101.36
3.39% yesterday
NYSE, Nov 25, 10:07 pm CET
ISIN
US1011371077
Symbol
BSX

Boston Scientific Stock price

$101.36
-1.07 1.04% 1M
-3.14 3.00% 6M
+12.04 13.48% YTD
+12.11 13.57% 1Y
+57.21 129.58% 3Y
+67.81 202.12% 5Y
+82.98 451.47% 10Y
+74.79 281.48% 20Y
NYSE, Closing price Tue, Nov 25 2025
+3.32 3.39%

New AI Insights on Boston Scientific Insights AI Insights on Boston Scientific

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$150.3b
Enterprise Value
$160.6b
Net debt
$10.3b
Cash
$1.3b
Shares outstanding
1.5b
Valuation (TTM | estimate)
P/E
54.5 | 33.1
P/S
7.8 | 7.4
EV/Sales
8.3 | 7.9
EV/FCF
42.0
P/B
6.4
Financial Health
Equity Ratio
55.3%
Return on Equity
8.5%
ROCE
10.0%
ROIC
8.1%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$19.4b | $20.3b
EBITDA
$4.6b | $6.1b
EBIT
$3.8b | $5.5b
Net Income
$2.8b | $4.5b
Free Cash Flow
$3.8b
Growth (TTM | estimate)
Revenue
21.6% | 21.0%
EBITDA
25.2% | 55.6%
EBIT
30.7% | 80.0%
Net Income
55.7% | 145.2%
Free Cash Flow
77.3%
Margin (TTM | estimate)
Gross
68.6%
EBITDA
24.0% | 30.0%
EBIT
19.4%
Net
14.4% | 22.4%
Free Cash Flow
19.8%
More
EPS
$1.9
FCF per Share
$2.6
Short interest
1.3%
Employees
53k
Rev per Employee
$320.0k
Show more

Is Boston Scientific a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,053 stocks worldwide.

Boston Scientific Stock Analysis

Unlock Scores for Free

Analyst Opinions

41 Analysts have issued a Boston Scientific forecast:

38x Buy
93%
3x Hold
7%

Analyst Opinions

41 Analysts have issued a Boston Scientific forecast:

Buy
93%
Hold
7%

Financial data from Boston Scientific

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
19,350 19,350
22% 22%
100%
- Direct Costs 6,082 6,082
24% 24%
31%
13,268 13,268
21% 21%
69%
- Selling and Administrative Expenses 6,666 6,666
16% 16%
34%
- Research and Development Expense 1,942 1,942
28% 28%
10%
4,648 4,648
25% 25%
24%
- Depreciation and Amortization 894 894
6% 6%
5%
EBIT (Operating Income) EBIT 3,754 3,754
31% 31%
19%
Net Profit 2,791 2,791
56% 56%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Boston Scientific directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Boston Scientific Stock News

Neutral
Seeking Alpha
8 days ago
Boston Scientific Corporation ( BSX ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 8:00 AM EST Company Participants Ken Stein - Senior VP & Global Chief Medical Officer Lauren Tengler - Director of Investor Relations Conference Call Participants Michael Polark - Wolfe Research, LLC Presentation Michael Polark Wolfe Research, LLC Good morning. Welcome, everybody.
Neutral
Seeking Alpha
20 days ago
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campaigns in Atlassian, Adidas and Vertex Pharmaceuticals during the quarter.
Neutral
PRNewsWire
23 days ago
MARLBOROUGH, Mass. , Nov. 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
More Boston Scientific News

Company Profile

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Head office United States
CEO Michael Mahoney
Employees 53,000
Founded 1979
Website www.bostonscientific.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today